FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913628032> ?p ?o ?g. }

• W2913628032 endingPage "1564" @default.
• W2913628032 startingPage "1564" @default.
• W2913628032 abstract "Abstract Primary mediastinal large B-cell lymphomas (PMBL) typically occur in young women who present with localized, large mediastinal masses. These tumors share certain clinical, pathomorphological and transcriptional features with classical Hodgkin lymphoma (cHL). To date, PMBL genetic analyses focused on limited sets of genes and recurrent somatic copy number alterations (SCNAs). Previously, we identified frequent 9p24.1/PD-L1/PD-L2 copy gains and increased expression of the PD-1 ligands as a genetically-defined immune escape mechanism in PMBL. The demonstrated efficacy of PD-1 blockade in relapsed/refractory PMBL led to recent FDA approval and underscored the importance of characterizing targetable genetic vulnerabilities in this disease. For these reasons, we obtained diagnostic biopsy specimens from 37 patients with PMBL (median age 34; female 70%) and performed whole exome sequencing (WES) with an expanded bait set to capture structural variants (SVs). Somatic alterations (mutations, SCNAs and SVs) were determined using established analytical pipelines including our algorithm for evaluating tumors without paired normal samples. Genes more frequently mutated than by chance, Candidate Cancer Genes (CCGs), were identified with MutSig2CV and recurrent SCNAs were defined with GISTIC2.0. SVs were characterized with a recently described 4-algorithm pipeline (Nature Medicine, 2018;24(5):679-690). First, we identified 15 CCGs (q-value <0.1) including genes with known roles in PMBL, such as IL4R and TNFAIP3 and mutational drivers in additional B-cell lymphomas (B2M, GNA13, STAT6, IKZF3, XPO1, TP53, PAX5) and other cancers (TP53, ZNF217 and XPO1). Overlaying the predicted protein changes onto available 3D protein structures highlighted the likely biological functions of specific alterations, such as mutational clustering in the STAT6 DNA-binding domain. We next analyzed the PMBL mutational signatures and identified 3 cases as hypermutators with MSI signatures, including 2 with MLH1 frameshift mutations and 1 with a nonsense PMS2 mutation. Despite the young age of the PMBL patient cohort, the majority of remaining mutations were caused by spontaneous deamination at CpGs, a genetic signature usually associated with aging. The next most prevalent mutational signatures were APOBEC and, infrequently, AID. We observed a higher median mutational density in PMBL (7.56 mutations/MB), compared to diffuse large B-cell lymphoma (DLBCL) and most solid cancers, providing a potential basis for increased neoantigen production and responsiveness to PD-1 blockade. Next, we identified 18 recurrent SCNAs, including 10 copy gains (2 focal and 8 arm level) and 8 copy losses (7 focal and 1 arm level). Copy gains of 9p24.1/PD-L1/PD-L2 were detected in 70% of cases. SVs were defined at base-pair resolution and included infrequent (2/37) tandem duplications of both PD-1 ligands and inactivating CTIIA SVs (deletions and inversions) in 10% (4/37) of cases. Although PMBL had a higher mutational density than DLBCL, the PMBL alterations involved a smaller number of median genetic drivers (9 [PMBL] vs 17 [DLBCL], respectively). Combined analyses of recurrent CCGs, SCNAs and SVs revealed that certain candidate driver genes were perturbed by multiple mechanisms. Examples include: TNFAIP3 (59% overall, 41% mutations, 24% copy loss, 6% biallelic); and B2M (51% overall, 30% mutations, 27% copy loss, 6% biallelic). Concurrent analyses of the 3 types of genetic alterations also revealed multiple bases of perturbing specific signaling pathways. In this PMBL series, 73% (27/33) of tumors exhibited one or more alterations of JAK/STAT pathway components: IL4R mutations (32%), JAK2 (9p24.1 focal copy gain [70%]) and STAT6 mutations (43%). Additionally, 59% of PMBLs had alterations of antigen presentation pathway components including B2M copy loss or mutations, copy loss of 6q21.33 (which includes the HLA class I/II loci) and SVs of CTIIA. These findings provide a genetic framework for analyzing the precise mechanism of action of PD-1 blockade in PMBL. Taken together, these findings underscore the importance of a comprehensive genomic analysis in PMBL and define additional candidate treatment targets and pathogenetic mechanisms in this disease. ____ BC, CS and AD contributed equally. GG and MAS contributed equally. Disclosures Rodig: Merck: Research Funding; KITE: Research Funding; Affimed: Research Funding; Bristol Myers Squibb: Research Funding. Shipp:Merck: Research Funding; AstraZeneca: Honoraria; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding." @default.
• W2913628032 created "2019-02-21" @default.
• W2913628032 creator A5000496024 @default.
• W2913628032 creator A5001392592 @default.
• W2913628032 creator A5003120045 @default.
• W2913628032 creator A5016610225 @default.
• W2913628032 creator A5021363179 @default.
• W2913628032 creator A5022657765 @default.
• W2913628032 creator A5033656253 @default.
• W2913628032 creator A5050754309 @default.
• W2913628032 creator A5058975989 @default.
• W2913628032 creator A5070357190 @default.
• W2913628032 creator A5074215180 @default.
• W2913628032 creator A5079809176 @default.
• W2913628032 creator A5087362622 @default.
• W2913628032 date "2018-11-29" @default.
• W2913628032 modified "2023-09-26" @default.
• W2913628032 title "Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma" @default.
• W2913628032 doi "https://doi.org/10.1182/blood-2018-99-118135" @default.
• W2913628032 hasPublicationYear "2018" @default.
• W2913628032 type Work @default.
• W2913628032 sameAs 2913628032 @default.
• W2913628032 citedByCount "4" @default.
• W2913628032 countsByYear W29136280322019 @default.
• W2913628032 countsByYear W29136280322020 @default.
• W2913628032 countsByYear W29136280322022 @default.
• W2913628032 crossrefType "journal-article" @default.
• W2913628032 hasAuthorship W2913628032A5000496024 @default.
• W2913628032 hasAuthorship W2913628032A5001392592 @default.
• W2913628032 hasAuthorship W2913628032A5003120045 @default.
• W2913628032 hasAuthorship W2913628032A5016610225 @default.
• W2913628032 hasAuthorship W2913628032A5021363179 @default.
• W2913628032 hasAuthorship W2913628032A5022657765 @default.
• W2913628032 hasAuthorship W2913628032A5033656253 @default.
• W2913628032 hasAuthorship W2913628032A5050754309 @default.
• W2913628032 hasAuthorship W2913628032A5058975989 @default.
• W2913628032 hasAuthorship W2913628032A5070357190 @default.
• W2913628032 hasAuthorship W2913628032A5074215180 @default.
• W2913628032 hasAuthorship W2913628032A5079809176 @default.
• W2913628032 hasAuthorship W2913628032A5087362622 @default.
• W2913628032 hasConcept C104317684 @default.
• W2913628032 hasConcept C121608353 @default.
• W2913628032 hasConcept C16671776 @default.
• W2913628032 hasConcept C203014093 @default.
• W2913628032 hasConcept C2778559949 @default.
• W2913628032 hasConcept C2779338263 @default.
• W2913628032 hasConcept C2780265364 @default.
• W2913628032 hasConcept C2781187634 @default.
• W2913628032 hasConcept C501734568 @default.
• W2913628032 hasConcept C502942594 @default.
• W2913628032 hasConcept C54355233 @default.
• W2913628032 hasConcept C86803240 @default.
• W2913628032 hasConceptScore W2913628032C104317684 @default.
• W2913628032 hasConceptScore W2913628032C121608353 @default.
• W2913628032 hasConceptScore W2913628032C16671776 @default.
• W2913628032 hasConceptScore W2913628032C203014093 @default.
• W2913628032 hasConceptScore W2913628032C2778559949 @default.
• W2913628032 hasConceptScore W2913628032C2779338263 @default.
• W2913628032 hasConceptScore W2913628032C2780265364 @default.
• W2913628032 hasConceptScore W2913628032C2781187634 @default.
• W2913628032 hasConceptScore W2913628032C501734568 @default.
• W2913628032 hasConceptScore W2913628032C502942594 @default.
• W2913628032 hasConceptScore W2913628032C54355233 @default.
• W2913628032 hasConceptScore W2913628032C86803240 @default.
• W2913628032 hasIssue "Supplement 1" @default.
• W2913628032 hasLocation W29136280321 @default.
• W2913628032 hasOpenAccess W2913628032 @default.
• W2913628032 hasPrimaryLocation W29136280321 @default.
• W2913628032 hasRelatedWork W2109788976 @default.
• W2913628032 hasRelatedWork W2115359326 @default.
• W2913628032 hasRelatedWork W2167040496 @default.
• W2913628032 hasRelatedWork W2464313322 @default.
• W2913628032 hasRelatedWork W2610466115 @default.
• W2913628032 hasRelatedWork W3008207576 @default.
• W2913628032 hasRelatedWork W3009829673 @default.
• W2913628032 hasRelatedWork W4226377937 @default.
• W2913628032 hasRelatedWork W4361235556 @default.
• W2913628032 hasRelatedWork W4361235565 @default.
• W2913628032 hasVolume "132" @default.
• W2913628032 isParatext "false" @default.
• W2913628032 isRetracted "false" @default.
• W2913628032 magId "2913628032" @default.
• W2913628032 workType "article" @default.